Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Transaction Costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept gyre:TransactionCosts.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Gyre Pharmaceuticals | Gyre | Total |
|---|---|---|---|
| Research and development | 9,697 | 4,603 | 14,300 |
| Research and development - related parties | 4,836 | — | 4,836 |
| General and administrative | 4,268 | 3,594 | 7,862 |
| Transaction costs | — | 502 | 502 |
| Total segment operating expenses | 34,764 | 8,699 | 43,463 |
| Loss from segment operations | (5,667) | (8,691) | (14,358) |
| Other segment (loss) income, net: | |||
| Interest income | 252 | 488 | 740 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — transaction costs?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — transaction costs of $0 in Q2 2026.
- What does gyre pharmaceuticals — transaction costs mean?
- This captures the non-recurring expenses directly related to the execution of specific business transactions, such as acquisitions, divestitures, or strategic partnerships. Tracking these costs helps investors isolate the impact of one-time corporate activities from core operational performance.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — transaction costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude